Αποτελέσματα Αναζήτησης
2 Σεπ 2021 · The incremental cost-effectiveness ratio (ICER) of AC-TH versus TCH was $US 52,565 per QALY gained. Conclusions. TCH neoadjuvant chemotherapy was feasible and active in HER2-overexpressing breast cancer patients in terms of the pathological complete response, complete response, and partial response rates and manageable toxicities. Key messages.
An adaptive-treatment strategy beginning with neoadjuvant THP or TH followed by tailoring post-operative therapy reduces treatment costs, and spares toxicity compared to more intensive chemotherapy regimens for women with HER2-positive breast cancer.
23 Φεβ 2021 · The aim of this paper was to evaluate the cost effectiveness of adjuvant AC-TH compared with TCH in the hospital setting for women with early (regional) breast cancer to help guide funding decisions for incurring breast cancer.
5 Ιουν 2019 · Compared to NT, TH has incremental cost-effectiveness ratios ranged from $10,584 (ages 40–49) to $84,981 (age 80+) per additional QALYs. The sensitivity analysis showed that TH is cheaper and leads to higher QALYs compared to both ACTH and TCH for all age groups and time horizons.
31 Ιουλ 2017 · An analysis of the SEER-Medicare database shows that outcomes and healthcare costs for the two chemotherapy regimens are similar, with one difference.
1 Σεπ 2021 · The incremental cost-effectiveness ratio (ICER) of AC-TH versus TCH was $US 52,565 per QALY gained. Conclusions TCH neoadjuvant chemotherapy was feasible and active in HER2-overexpressing...
19 Ιουν 2024 · We performed a univariate analysis using log-rank testing to compare survival outcomes between those who received adjuvant trastuzumab, with or without chemotherapy, to those who did not.
